艾美疫苗预计2024年收入为12.5亿元至13亿元

财中社
17 Mar

  3月17日,艾美疫苗(06660)发布公告,预计截至2024年12月31日的报告期间,本集团未经审计的收入将介于12.5亿元至13亿元之间,较上一年度的11.9亿元增加6000万至1.1亿,增幅为5%至9%。

  同时,预计未审计的净亏损将介于2.5亿元至2.9亿元,较上一年度的净亏损19.5亿元大幅减少,减亏幅度为85%至87%。

  公告指出,收入增加的主要原因是公司乙肝疫苗的销售增长,而综合净亏损减少则是由于本年度大额资产减值损失的金额减少及收入的提升。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10